Musa Tariq Sells 3,213 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 3,213 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total value of $158,947.11. Following the completion of the transaction, the director now directly owns 7,190 shares of the company's stock, valued at approximately $355,689.30. The trade was a 30.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Musa Tariq also recently made the following trade(s):

• On Monday, May 19th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $40.04, for a total value of $4,644.64.
• On Thursday, April 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $44.79, for a total value of $5,195.64.

Guardant Health Stock Down 2.8%

NASDAQ:GH traded down $1.43 on Friday, hitting $49.14. The stock had a trading volume of 2,161,505 shares, compared to its average volume of 2,138,716. The business's fifty day moving average is $44.45 and its 200 day moving average is $42.05. The company has a market cap of $6.09 billion, a PE ratio of -14.50 and a beta of 1.37. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 53.82%. The company's quarterly revenue was up 20.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.46) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. bought a new position in Guardant Health in the first quarter worth approximately $12,634,000. Rhumbline Advisers lifted its holdings in shares of Guardant Health by 4.9% in the first quarter. Rhumbline Advisers now owns 175,432 shares of the company's stock valued at $7,473,000 after purchasing an additional 8,202 shares in the last quarter. Strs Ohio bought a new position in shares of Guardant Health in the first quarter valued at approximately $809,000. Intech Investment Management LLC lifted its holdings in shares of Guardant Health by 37.3% in the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock valued at $2,564,000 after purchasing an additional 16,363 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Guardant Health by 6.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company's stock valued at $118,302,000 after purchasing an additional 164,263 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GH shares. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Stephens reissued an "overweight" rating and issued a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. UBS Group increased their price target on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Raymond James Financial reissued an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Finally, Stifel Nicolaus increased their price target on Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $53.76.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.